Regarding immunotherapy with aniti-PD-1/PD-L1 antibody, pretreatment serum CRP concentrations emerged as independent predictors of both PFS and OS rates in R/M cervical cancer patients undergoing immunotherapeutic interventions (53). This evidence concerns the gene CRP and cervical carcinoma.